Bioanalysis of therapeutic peptides: differentiating between total and anti-drug antibody bound drug using liquid chromatography-tandem mass spectrometry quantitation.

J Chromatogr A

F. Hoffmann-La Roche Ltd., Non-Clinical Drug Safety, DMPK and Bioanalytical R&D, Basel, Switzerland. Electronic address:

Published: November 2013

An acylated peptide with MW ~4.5 kDa was measured in samples from pharmacokinetic, toxicology and clinical studies using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Lower limits of quantitation of 2 ng/mL and 50 pg/mL were achieved for animal and human plasma, respectively. Repeated drug administration may lead to anti-drug antibodies (ADA) which can inactivate the drug by formation of drug-ADA complexes. Hence, the LC-MS/MS assay incorporated cleavage of potential drug-ADA complexes to quantify the total plasma concentration. To obtain information on active drug levels, an assay that measures the free concentration or alternatively the ADA-unbound concentration would be needed. Ultrafiltration experiments through 100 kD cutoff membranes to remove Ig-bound peptide were not successful due to nonspecific binding. Extraction of Ig-bound drug using Protein A or G (bacterial cell wall proteins with high affinity to the Fc region of IgG) was suitable to distinguish between ADA-bound drug and [free+protein bound (not ADA-bound)] drug and correlated with findings from ELISA ADA measurement.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chroma.2013.09.073DOI Listing

Publication Analysis

Top Keywords

liquid chromatography-tandem
8
chromatography-tandem mass
8
mass spectrometry
8
drug-ada complexes
8
drug
7
bioanalysis therapeutic
4
therapeutic peptides
4
peptides differentiating
4
differentiating total
4
total anti-drug
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!